Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 29300-171

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 29300-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 01

Chemical structure of memantine hydrochloride, depicting its cage-like adamantane framework with labeled functional groups including amine (NH2) and methyl groups (CH3).*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 02

A line graph comparing mean change from baseline in the ADCS-ADL score over 28 weeks of treatment between placebo and memantine hydrochloride. The graph shows clinical improvement and decline, with data points and error bars indicating variability for each treatment group across weeks 0, 4, 12, and 28.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 03

A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Memantine Hydrochloride and placebo groups. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. Two curves represent placebo (squares) and Memantine Hydrochloride (circles) treatment responses.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 04

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride to placebo. The Y-axis represents the change in SIB score ranging from clinical decline to clinical improvement, while the X-axis shows weeks of treatment. Memantine Hydrochloride shows less decline over time compared to placebo.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 05

A cumulative percentage curve graph comparing patients treated with Memantine Hydrochloride and placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, while the y-axis shows the cumulative percentage of patients. The graph includes two curves labeled as Memantine Hydrochloride and Placebo, indicating different response distributions over the SIB change range.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 06

A line graph comparing mean change from baseline in ADCS-ADL scores over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The y-axis shows mean change scores indicating clinical improvement or decline. The x-axis represents weeks of treatment, showing overall greater improvement/stabilization in the Memantine Hydrochloride/Donepezil group compared to placebo.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 07

A cumulative percentage of patients chart comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The x-axis represents ADCS-ADL change from baseline, ranging from approximately -25 to 15. The y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves display patient response distributions, with Memantine Hydrochloride/Donepezil generally showing a higher cumulative percentage at lower ADCS-ADL changes than Placebo/Donepezil.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 08

A line graph depicting mean change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The vertical axis shows mean change with error bars, and the horizontal axis shows weeks of treatment. The graph highlights trends toward clinical improvement or decline during the period.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 09

A cumulative percentage of patients chart comparing the effects of Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents change from baseline in SIB scores, and the y-axis shows cumulative percentage of patients. Two distinct curves represent the two treatment groups over the range of SIB change values.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 10

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 11

Memantine Hydrochloride 5 mg film-coated tablets bottle label, USP, containing 60 tablets. The label states usual dosage instructions refer to the package insert. Manufactured by Unichem Laboratories Ltd. in India and for Unichem Pharmaceuticals (USA), Inc. The label includes storage instructions and a barcode.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 12

Label for Memantine Hydrochloride tablets, USP, 10 mg strength, film-coated oral tablets. The label states the product is dispensed only by prescription, contains 60 tablets per container, and is labeled by Unichem Pharmaceuticals (USA), Inc. It includes storage instructions, dosage information referencing an accompanying package insert, and manufacturer details indicating Unichem Laboratories Ltd. in India and Unichem Pharmaceuticals (USA) Inc. in New Jersey.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.